Table 2.
Associations of HLA-DR genetic polymorphisms with HCC risk
| SNPs | Genotype | Healthy controls (%) | CHB plus LC (%) | HCC (%) | HCC versus. Healthy controls | HCC versus. HBV-infected subjects without HCC | |||
|---|---|---|---|---|---|---|---|---|---|
| AORa (95% CI) | P value | AORb (95% CI) | P value | ||||||
| rs3135363 | AA | 465 (58.71) | 712 (63.46) | 1006 (67.07) | Reference | Reference | |||
| AG | 276 (34.85) | 331 (29.50) | 438 (29.20) | 0.74 (0.61–0.89) | 0.001 | 0.93 (0.79–1.11) | 0.434 | ||
| GG | 51 (6.44) | 79 (7.04) | 56 (3.73) | 0.52 (0.35–0.77 | 0.001 | 0.51 (0.36–0.73) | 1.97 × 10 − 4 | ||
| AG + GG | 327 (41.29) | 410 (36.54) | 494 (32.93) | 0.70 (0.55–0.90) | 9.59 × 10 − 5 | 0.85 (0.73–1.03) | 0.054 | ||
| rs9268644 | CC | 484 (61.11) | 631 (56.24) | 998 (66.53) | Reference | Reference | |||
| CA | 264 (33.33) | 365 (32.53) | 394 (26.27) | 0.72 (0.66–0.88) | 0.001 | 0.68 (0.57–0.81) | 1.32 × 10 − 5 | ||
| AA | 44 (5.56) | 126 (11.23) | 108 (7.20) | 1.19 (0.83–1.72) | 0.352 | 0.54 (0.41–0.71) | 1.26 × 10 − 5 | ||
| CA + AA | 308 (38.89) | 491 (43.76) | 502 (33.47) | 0.79 (0.66–0.95) | 0.010 | 0.64 (0.55–0.76) | 6.33 × 10 − 8 | ||
| rs35445101 | AA | 531 (67.05) | 770 (68.63) | 1152 (76.80) | Reference | Reference | |||
| AG | 95 (11.99) | 130 (11.59) | 158 (10.53) | 0.78 (0.59–1.02) | 0.071 | 0.81 (0.63–1.04) | 0.102 | ||
| GG | 166 (20.96) | 222 (19.79) | 190 (12.67) | 0.53 (0.42–0.67) | 7.38 × 10 − 8 | 0.57 (0.46–0.71) | 3.18 × 10 − 7 | ||
| AG + GG | 261 (32.95) | 352 (31.37) | 348 (23.20) | 0.62 (0.51–0.75) | 7.64 × 10 − 7 | 0.66 (0.56–0.79) | 3.06 × 10 − 6 | ||
| rs24755213 | AA | 268 (33.84) | 404 (36.01) | 609 (40.60) | Reference | Reference | |||
| AG | 392 (49.49) | 508 (45.28) | 635 (42.33) | 0.74 (0.61–0.89) | 0.002 | 0.85 (0.72–1.02) | 0.073 | ||
| GG | 132 (16.67) | 210 (18.71) | 256 (17.07) | 0.88 (0.68–1.14) | 0.323 | 0.83 (0.67–1.04) | 0.104 | ||
| AG + GG | 524 (66.16) | 718 (63.99) | 891 (59.40) | 0.77 (0.64–0.93) | 0.005 | 0.85 (0.72–0.99) | 0.044 | ||
| rs984778 | TT | 358 (45.20) | 603 (53.74) | 813 (54.20) | Reference | Reference | |||
| TC | 344 (43.43) | 429 (38.24) | 574 (38.27) | 0.74 (0.61–0.88) | 0.001 | 1.02 (0.86–1.20) | 0.858 | ||
| CC | 90 (11.37) | 90 (8.02) | 113 (7.53) | 0.55 (0.41–0.74) | 1.13 × 10 − 4 | 0.94 (0.70–1.27) | 0.693 | ||
| TC + CC | 434 (54.80) | 519 (46.26) | 687 (45.80) | 0.70 (0.55–0.89) | 0.004 | 0.99 (0.85–1.17) | 0.976 | ||
a AOR, odds ratio adjusted for age, gender, ALT, AST in the comparison between HCC and Healthy controls
b AOR, odds ratio adjusted for age, gender, HBeAg, HBV DNA load, ALT, and AST in the comparison between HCC and HBV-infected subjects without HCC.
CI confidence interval, HBV hepatitis B virus, HCC hepatocellular carcinoma, HLA human leukocyte antigen, SNP single nucleotide polymorphism
Boldface type indicates significant values, and the difference was significant. Statistically significant levels were corrected using the Bonferroni correction for multiple comparisons [P = 0.025 (two comparisons)]